Analysed COCRYSTAL PHARMA INC (COCP:NASDAQ) News Sources
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention
07-04-2026
yahoo.com
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
02-04-2026
yahoo.com
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
31-03-2026
yahoo.com
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
09-03-2026
yahoo.com
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
19-02-2026
yahoo.com
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
18-12-2025
yahoo.com
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
01-12-2025
yahoo.com
What is the current price of COCRYSTAL PHARMA INC (COCP:NASDAQ)?
The current price of COCRYSTAL PHARMA INC (COCP:NASDAQ) is $1.25.
COCRYSTAL PHARMA INC (COCP:NASDAQ) absolute price change since previous trading day?
The absolute price change of COCRYSTAL PHARMA INC (COCP:NASDAQ) since the previous trading day is $-0.18.
COCRYSTAL PHARMA INC (COCP:NASDAQ) percentage price change since previous trading day?
The percentage price change of COCRYSTAL PHARMA INC (COCP:NASDAQ) since the previous trading day is -12.5874%.
What is the most recent average sentiment score for COCRYSTAL PHARMA INC (COCP:NASDAQ)?
The most recent average sentiment score for COCRYSTAL PHARMA INC (COCP:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for COCRYSTAL PHARMA INC (COCP:NASDAQ)?
The most recent sentiment for COCRYSTAL PHARMA INC (COCP:NASDAQ) is .
SEC-8K** Filing Available For COCRYSTAL PHARMA INC (COCP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.